Viva Biotech Holdings (incorporated in the Cayman Islands with limited liability) filed a Next Day Disclosure Return with the Hong Kong Stock Exchange on 15 June 2026, detailing the latest activity under its share repurchase programme.

Key points

1. Latest repurchase – 15 June 2026 • Shares bought: 500,000 ordinary shares • Price range: HK$1.18–HK$1.19 per share • Total consideration: HK$0.59 million • Purpose: cancellation (no treasury shares will be held)

2. Cumulative activity since 8 May 2026 • Total shares repurchased but not yet cancelled: 28.59 million • Represents: 1.34 % of issued shares as at the 12 June 2025 mandate date • Average prices: HK$1.14–HK$1.57 per share across individual trading days

3. Capital structure • Issued shares outstanding (excluding treasury shares) remained unchanged at 2.13 billion as at both 12 June and 15 June 2026. • No treasury shares are recorded on the balance sheet.

4. Repurchase mandate utilisation • Shares authorised under the 12 June 2025 mandate: 212.84 million • Shares repurchased to date under the mandate: 28.59 million • Utilisation of mandate: 13.44 % • Moratorium on new share issues or treasury share transfers applies until 15 July 2026, in accordance with Hong Kong listing rules.

The company confirmed that all repurchases were executed on the Stock Exchange of Hong Kong, fully authorised by the board, and compliant with all applicable listing and regulatory requirements.